STELLA PHARMA CORPORATION
ステラファーマ株式会社
Valuation
Fundamental ratios for the latest reported period.
Ticker: 4888
FY2025 (Mar 2026) · J-GAAP · parent-only (non-consolidated) Source: filing S100YDYN
FY = fiscal year, named by the calendar year it starts in; the month in brackets is when it ends (FY2025 ends Mar 2026 for a March year-end). FY2025 (Mar 2026) runs Apr 1, 2025 – Mar 31, 2026.
| Gross margin | 86.3% |
|---|---|
| Operating margin | -231.6% |
| Net margin | -241.5% |
| Return on equity | -27.7%Includes one-off items (e.g. gains on negative goodwill) |
| Return on assets | -15.8% |
| Revenue growth (YoY) | -66.4% |
| EPS (basic) | −¥22.95 |
| EPS growth (YoY) | —Base is zero or negative |
| Current ratio | 16.75x |
| Equity ratio | 54.1% |
| Book value / share | ¥71.33 |
| Free cash flow | −¥346M |